BR112023016801A2 - Composto tricíclico como inibidor de hif2a, método de preparação e aplicação do mesmo - Google Patents
Composto tricíclico como inibidor de hif2a, método de preparação e aplicação do mesmoInfo
- Publication number
- BR112023016801A2 BR112023016801A2 BR112023016801A BR112023016801A BR112023016801A2 BR 112023016801 A2 BR112023016801 A2 BR 112023016801A2 BR 112023016801 A BR112023016801 A BR 112023016801A BR 112023016801 A BR112023016801 A BR 112023016801A BR 112023016801 A2 BR112023016801 A2 BR 112023016801A2
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitor
- application
- preparation
- hif2a
- tricyclic compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 102100036448 Endothelial PAS domain-containing protein 1 Human genes 0.000 title 1
- 101000851937 Homo sapiens Endothelial PAS domain-containing protein 1 Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
composto tricíclico como inibidor de hif2a, método de preparação e aplicação do mesmo. um composto tricíclico conforme representado pela fórmula (i), um método de preparação para o mesmo e uma aplicação do mesmo como um inibidor de hif2a.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110203800 | 2021-02-23 | ||
| CN202210095335 | 2022-01-26 | ||
| CN202210135655 | 2022-02-14 | ||
| PCT/CN2022/077454 WO2022179524A1 (zh) | 2021-02-23 | 2022-02-23 | 作为HIF2α抑制剂的三并环类化合物及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023016801A2 true BR112023016801A2 (pt) | 2023-12-05 |
Family
ID=83047788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023016801A BR112023016801A2 (pt) | 2021-02-23 | 2022-02-23 | Composto tricíclico como inibidor de hif2a, método de preparação e aplicação do mesmo |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240158367A1 (pt) |
| EP (1) | EP4299570A1 (pt) |
| JP (1) | JP2024508773A (pt) |
| KR (1) | KR20230145140A (pt) |
| CN (1) | CN116724035A (pt) |
| AU (1) | AU2022227066A1 (pt) |
| BR (1) | BR112023016801A2 (pt) |
| CA (1) | CA3209212A1 (pt) |
| IL (1) | IL305405A (pt) |
| TW (1) | TW202302559A (pt) |
| WO (1) | WO2022179524A1 (pt) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2931085C (en) * | 2013-12-16 | 2021-10-19 | Peloton Therapeutics, Inc. | Cyclic sulfone and sulfoximine analogs and uses thereof |
| WO2016057242A1 (en) * | 2014-10-10 | 2016-04-14 | The Board Of Regents Of The University Of Texas System | HIF-2α INHIBITORS FOR TREATING IRON OVERLOAD DISORDERS |
| US9796697B2 (en) * | 2015-06-12 | 2017-10-24 | Peloton Therapeutics, Inc. | Tricyclic inhibitors of HIF-2-alpha and uses thereof |
| WO2018031680A1 (en) * | 2016-08-10 | 2018-02-15 | Fronthera U.S. Pharmaceuticals Llc | Novel compounds, uses and methods for their preparation |
| JP2022529166A (ja) * | 2019-04-18 | 2022-06-17 | ニカン セラピューティクス，インコーポレイテッド | 低酸素誘導因子２（アルファ）阻害剤としてのテトラヒドロ－１Ｈ－シクロペンタ［ｃｄ］インデン誘導体 |
| US20220274914A1 (en) * | 2019-07-22 | 2022-09-01 | Nikang Therapeutics, Inc. | Tricyclic derivatives as hypoxia inducible factor-2(alpha) inhibitors |
-
2022
- 2022-02-23 US US18/278,340 patent/US20240158367A1/en active Pending
- 2022-02-23 AU AU2022227066A patent/AU2022227066A1/en active Pending
- 2022-02-23 WO PCT/CN2022/077454 patent/WO2022179524A1/zh active Application Filing
- 2022-02-23 TW TW111106640A patent/TW202302559A/zh unknown
- 2022-02-23 KR KR1020237030901A patent/KR20230145140A/ko unknown
- 2022-02-23 EP EP22758888.6A patent/EP4299570A1/en active Pending
- 2022-02-23 IL IL305405A patent/IL305405A/en unknown
- 2022-02-23 BR BR112023016801A patent/BR112023016801A2/pt unknown
- 2022-02-23 CN CN202280010622.5A patent/CN116724035A/zh active Pending
- 2022-02-23 CA CA3209212A patent/CA3209212A1/en active Pending
- 2022-02-23 JP JP2023550130A patent/JP2024508773A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022227066A1 (en) | 2023-10-05 |
| EP4299570A1 (en) | 2024-01-03 |
| JP2024508773A (ja) | 2024-02-28 |
| TW202302559A (zh) | 2023-01-16 |
| WO2022179524A1 (zh) | 2022-09-01 |
| KR20230145140A (ko) | 2023-10-17 |
| CN116724035A (zh) | 2023-09-08 |
| US20240158367A1 (en) | 2024-05-16 |
| IL305405A (en) | 2023-10-01 |
| CA3209212A1 (en) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002696A1 (es) | Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma | |
| BR112021024108A2 (pt) | Inibidores de tead e usos dos mesmos | |
| PH12018501099A1 (en) | Novel biphenyl compound or salt thereof | |
| AR111304A1 (es) | Métodos para sintetizar un inhibidor de mcl-1 | |
| EA202092263A1 (ru) | Аминопиридиновые производные в качестве ингибиторов ctps1 | |
| CY1124450T1 (el) | Νουκλεοτιδια βητα-νικοτινικου εστερα και διεργασιες για την παρασκευη αυτων | |
| EA201790800A1 (ru) | Замещенные производные бензотиофенила в качестве агонистов gpr40 для лечения диабета ii типа | |
| CL2023000594A1 (es) | Compuestos heterocíclicos | |
| BR112017022281A2 (pt) | métodos para tratar câncer | |
| CL2021000292A1 (es) | Benzimidazoles sustituidos como inhibidores de pad4. | |
| CL2017000484A1 (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| CL2022000019A1 (es) | Nuevos compuestos heterocíclicos | |
| ZA202101487B (en) | Novel compounds | |
| CL2022001492A1 (es) | Nuevos inhibidores de braf como rompedores de la paradoja | |
| BR112017022269A2 (pt) | métodos para tratar câncer | |
| CL2020002217A1 (es) | Uso de alcoxipirazoles como inhibidores de la nitrificación | |
| BR112021026556A2 (pt) | Composto tricíclico, método de preparação para ele e uso dele | |
| CO2022009068A2 (es) | Composición para la inhibición de la producción de hmf que comprende disacárido de alulosa | |
| BR112023020274A2 (pt) | Método de preparo de composto bicíclico e aplicação como agente antifúngico | |
| BR112018076734A2 (pt) | compostos heterocíclicos anti-infecciosos e usos dos mesmos | |
| BR112018074287A2 (pt) | processo para preparação de eribulina e intermediários da mesma | |
| BR112021023886A2 (pt) | Compostos tetracíclicos como inibidores de cdc7 | |
| BR112021026061A2 (pt) | Método para o tratamento de uma composição que compreende vanilina natural | |
| BR112023016801A2 (pt) | Composto tricíclico como inibidor de hif2a, método de preparação e aplicação do mesmo | |
| EA202190989A1 (ru) | Новый способ синтеза производных пиперазинил-этокси-бромфенила и их применение в получении содержащих их соединений |